RT Journal Article
T1 Overcoming Glucocorticoid Resistances and Improving Antitumor Therapies: Lipid and Polymers Carriers
A1 Martín Sabroso, Cristina
A1 Moreno-Ortega, A. J.
A1 Aparicio Blanco, Juan
A1 Fraguas Sánchez, Ana Isabel
A1 Cano-Abad, M. F.
A1 Torres Suárez, Ana Isabel
AB PurposeTo improve chemotherapy protocols of lymphoid malignancies, by using polymeric and lipid microparticles as controlled delivery systems of dexamethasone, part of all combined chemotherapy protocols for its strong-inducing effect on malignant lymphoblasts.MethodsPolymeric microparticles were prepared by the oil-in-water-emulsion cosolvent evaporation method, andlipid microparticles by spray drying. Their cytotoxic effects on GC-sensitive PC12 cells and GC-resistant PC3 cells were characterized by cell proliferation and apoptosis assays.ResultsBoth elaboration methods rendered optimal-sized microparticles for parenteral administration with high drug loading. In vitro assays showed sustained dexamethasone release from polymeric microparticles over a month, whereas 100% dexamethasone release from lipid microparticles was achieved within 24 h. Similar PC12 cell death to that obtained with dexamethasone solution administered every 48 h was achieved with dexamethasone polymeric microparticles in 26-days assays. Dexamethasone solution and loaded polymeric microparticles induced apoptosis around 15.8 and 19.9%, respectively, after 2 days of incubation. Lipid microparticles increased further apoptosis induction in PC12 cells and, unlike dexamethasone solution and polymeric microparticles, showed antiproliferative effects on PC3 cells.ConclusionsDexamethasone polymeric microparticles constitute an alternative to current dexamethasone administration systems in combined chemotherapy, whereas dexamethasone lipid microparticles represent a potential tool to revert glucocorticoid resistance.
SN 0724-8741
YR 2014
FD 2014-09-12
LK https://hdl.handle.net/20.500.14352/97119
UL https://hdl.handle.net/20.500.14352/97119
LA eng
NO Universidad Complutense de Madrid
NO Banco Santander
NO Ministerio de Economía, Comercio y Empresa(España)
DS Docta Complutense
RD 1 abr 2026